Public Event Detail
Mizuho Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)
Public historical observation from the Merrowstone archive. This page shows event-level context only. Accepted assertions, evidence lineage, and relationship intelligence remain part of the premium research layer.
Historical observations only. No forecasts, recommendations, buy/sell ratings, or portfolio advice.
2026-04-01METAMeta PlatformsAlpha Vantage Newsearnings
Event summary
Mizuho Securities has reaffirmed its Buy rating on Crispr Therapeutics AG (CRSP) with an $85.00 price target. This comes despite a mixed analyst sentiment, as Piper Sandler also issued a Buy, while TipRanks – xAI reiterated a Hold rating. The company recently reported a quarterly GAAP net loss of $130.61 million, and corporate insider sentiment is positive with increased insider buying activity.
Attached public signals
Observed outcomes
7d returnPending
30d returnPending
90d returnPending
Relative 90d returnPending